New study aims to help people with disabilities suffering from uncontrollable movements

NCT ID NCT06997198

Recruiting now Disease control Sponsor: University Hospitals Cleveland Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests a drug called deutetrabenazine for tardive dyskinesia (uncontrollable movements) in 25 adults with intellectual/developmental disabilities and psychiatric or behavioral disorders. Participants will take the medication for 24 weeks to see if it reduces movement problems and improves daily life. The goal is to find a safe and effective treatment for this group, who often have trouble with standard movement exams.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEVELOPMENTAL DISABILITIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Caregiver Burden developmental disability intellectual disability movement disorder tardive dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEVELOPMENTAL DISABILITIES INTELLECTUAL DISABILITY TARDIVE DYSKINESIA

Contacts and locations

Locations

University Hospitals of Cleveland
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.